Somatostatin Receptor PET/CT in SSTR-Related Disease Patients

Launched by TIANJIN MEDICAL UNIVERSITY · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging test called PET/CT, which uses a radioactive substance to help doctors see tumors in patients with certain types of cancer related to somatostatin receptors (known as SSTR-related diseases). The main goal is to find out how useful this imaging test is for diagnosing both new and existing tumors, as well as for checking if cancer has spread to other parts of the body.

To participate in the trial, you need to be an adult aged 18 or older and have either suspected or newly diagnosed cancer. You should also be scheduled for an SSTR PET/CT scan and able to give your consent to join the study. Unfortunately, individuals with non-cancerous growths, those who are pregnant, or those who cannot provide consent cannot participate. If you join the study, you can expect to undergo the PET/CT scan, which will help researchers gather important information about the effectiveness of this imaging technique for your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.